April 6 (Reuters) - Bristol Myers Squibb (BMY.N), opens new tab said on Saturday data from late-stage studies of its experimental schizophrenia drug showed it helped reduce symptoms of the disorder without the common side effect of weight gain tied to other antipsychotics.The drugmaker gained access to the treatment, called KarXT, through its $14 billion deal to buy Karuna Therapeutics last year. Long-term data of the drug reinforced the findings that were seen in previous short-term studies, the company sa ...

With the market off to a rather wobbly start to the second quarter of 2024, investors may be looking for the most undervalued biotech stocks to buy in April that can offer more bang for one’s buck. For new investors seeking reasonable valuations and overlooked long-term growth drivers, the biotech scene is worth considering.With the rise of diabetes drugs, whose benefits may extend beyond losing weight (a recent study shed light on its ability to help treat Parkinson’s Disease potentially), the biotech indu ...

Bristol Myers Squibb (BMY) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the factors that might affect the near-term performance of the stock.Shares of this biopharmaceutical company have returned -2.3% over the past month versus the Zacks S&P 500 composite's +1.6% change. The Zacks Medical - Biomedical and Genetics industry, to which Bristol Myers belongs, has lost 3.5% over this period. Now the key question is: Where could the stock be headed ...

Bristol Myers Squibb (BMY) announced that the European Commission (EC) has approved a label expansion of Reblozyl (luspatercept).The EC expanded the drug’s label to include the first-line treatment of adult patients with transfusion-dependent anemia due to very low, low and intermediate-risk myelodysplastic syndromes (MDS). The approval of Reblozyl covers all European Union (EU) member states.The latest approval is based on results of the late-stage COMMANDS study, wherein Reblozyl demonstrated superior eff ...

monsitj Bristol-Myers Squibb, Inc. (NYSE:BMY) is in the health care sector and in the pharmaceutical industry. While not a factor in my analysis of the company, BMY is expected to have 2024 annual revenue of $45.85B and annual earnings per share of $6.83. BMY is also yielding a safe 4.43%. In this article I will outline why I think BMY is a speculative buy at this price. It is speculative because not all of my preferred parameters are in place yet as I will outline in the article. My investment thesis w ...

Core Insights - Three companies in the pharmaceuticals and healthcare sectors present significant investment opportunities due to their strategic growth initiatives and market positioning [1][2] Group 1: Bristol-Myers Squibb (BMY) - Bristol-Myers Squibb has enhanced its growth profile through strategic acquisitions, including RayzeBio, Mirati Therapeutics, and Karuna Therapeutics, which provide advanced platforms and pipeline assets [3] - The acquisition of Karuna Therapeutics supports the potential for multi-billion-dollar sales from KarXT, aimed at treating schizophrenia and Alzheimer's psychosis [3] - Strategic alliances, such as the one with SystImmune, provide unique technology and oncology resources, enhancing the company's market capabilities [4] Group 2: Walgreens Boots Alliance (WBA) - Walgreens Boots Alliance reported an 8.7% year-over-year increase in pharmacy comp sales in Q2 2024, driven by prescription volume growth and brand inflation [5] - The acquisition of Summit Health and collaboration with VillageMD have strengthened Walgreens Boots Alliance's healthcare service offerings [5][6] - Boots UK demonstrated resilience with a 3.2% year-over-year sales increase, supported by strategic initiatives and market share growth [6] Group 3: CVS Health (CVS) - CVS Health achieved $93.8 billion in consolidated Q4 revenues, reflecting an 11.9% year-over-year growth, and $357.8 billion in consolidated revenue for 2023, a 10.9% increase [7] - The Healthcare Benefits division reported approximately $27 billion in Q4 revenues, a significant rise of over 16% year-over-year, showcasing the segment's adaptability [7][8] - The Health Services segment generated over $49 billion in Q4 sales, indicating a growth of over 12% year-over-year, driven by strong pharmacy services and strategic acquisitions [8]

Bristol Myers (BMY) announced that a late-stage study on orally-administered Zeposia (ozanimod) in Crohn’s disease (CD) indication failed to achieve its primary endpoint.This late-stage study was the first of the two induction studies in the phase III YELLOWSTONE clinical program, which evaluated Zeposia in 600 adult patients with moderate to severe active CD over a 12-week treatment period. Initial results from the study showed that treatment with Zeposia failed to meet the primary endpoint of clinical rem ...

Biotech is an industry full of opportunity. It’s also known as one of the riskiest sectors to invest in. Why is this the case? Well, many of these companies are very small and focused on researching new drugs. These drugs, being their products, are thus in development and thus the future revenue is not assured. The future revenue hinges on successful FDA approvals and the ability to actually sell the drug. As such, this industry is known for companies that tank 50% in just days following poor clinical resul ...

Bristol Myers Squibb (BMY) ended the recent trading session at $51.59, demonstrating a -0.56% swing from the preceding day's closing price. This change lagged the S&P 500's daily gain of 0.32%. On the other hand, the Dow registered a gain of 0.68%, and the technology-centric Nasdaq increased by 0.2%.The biopharmaceutical company's shares have seen an increase of 1.91% over the last month, surpassing the Medical sector's gain of 0.88% and falling behind the S&P 500's gain of 5.11%.The investment community wi ...

Bristol Myers (BMY) announced that the European Commission (EC) has approved a label expansion for chimeric antigen receptor (CAR) T cell immunotherapy Abecma.The therapy is now approved in the European Union (EU) in earlier lines for triple-class exposed relapsed and refractory multiple myeloma.Abecma is already approved in the EU, Switzerland, Japan, the United Kingdom and Israel for adult patients with triple-class exposed relapsed or refractory multiple myeloma after three to four or more prior lines of ...